Abstract
The 1950s saw the clinical introduction of the first two specifically antidepressant drugs: iproniazid, a monoamine- oxidase inhibitor that had been used in the treatment of tuberculosis, and imipramine, the first drug in the tricyclic antidepressant family. Iproniazid and imipramine made two fundamental contributions to the development of psychiatry: one of a social-health nature, consisting in an authentic change in the psychiatric care of depressive patients; and the other of a purely pharmacological nature, since these agents have constituted an indispensable research tool for neurobiology and psychopharmacology, permitting, among other things, the postulation of the first aetiopathogenic hypotheses of depressive disorders. The clinical introduction of fluoxetine, a selective serotonin reuptake inhibitor, in the late 1980s, once again revolutionized therapy for depression, opening the way for new families of antidepressants. The present work reviews, from a historical perspective, the entire process that led to the discovery of these drugs, as well as their contribution to the development of the neuroscientific disciplines. However, all of these antidepressants, like the rest of those currently available for clinical practice, share the same action mechanism, which involves the modulation of monoaminergic neurotransmission at a synaptic level, so that the future of antidepressant therapy would seem to revolve around the search for extraneuronal non-aminergic mechanisms or mechanisms that modulate the intraneuronal biochemical pathways.
Keywords: Depression, antidepressants, iproniazid, imipramine, fluoxetine, monoaminergic neurotransmission, history
Current Pharmaceutical Design
Title: Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today
Volume: 15 Issue: 14
Author(s): Francisco Lopez-Munoz and Cecilio Alamo
Affiliation:
Keywords: Depression, antidepressants, iproniazid, imipramine, fluoxetine, monoaminergic neurotransmission, history
Abstract: The 1950s saw the clinical introduction of the first two specifically antidepressant drugs: iproniazid, a monoamine- oxidase inhibitor that had been used in the treatment of tuberculosis, and imipramine, the first drug in the tricyclic antidepressant family. Iproniazid and imipramine made two fundamental contributions to the development of psychiatry: one of a social-health nature, consisting in an authentic change in the psychiatric care of depressive patients; and the other of a purely pharmacological nature, since these agents have constituted an indispensable research tool for neurobiology and psychopharmacology, permitting, among other things, the postulation of the first aetiopathogenic hypotheses of depressive disorders. The clinical introduction of fluoxetine, a selective serotonin reuptake inhibitor, in the late 1980s, once again revolutionized therapy for depression, opening the way for new families of antidepressants. The present work reviews, from a historical perspective, the entire process that led to the discovery of these drugs, as well as their contribution to the development of the neuroscientific disciplines. However, all of these antidepressants, like the rest of those currently available for clinical practice, share the same action mechanism, which involves the modulation of monoaminergic neurotransmission at a synaptic level, so that the future of antidepressant therapy would seem to revolve around the search for extraneuronal non-aminergic mechanisms or mechanisms that modulate the intraneuronal biochemical pathways.
Export Options
About this article
Cite this article as:
Lopez-Munoz Francisco and Alamo Cecilio, Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today, Current Pharmaceutical Design 2009; 15 (14) . https://dx.doi.org/10.2174/138161209788168001
DOI https://dx.doi.org/10.2174/138161209788168001 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Ever Changing Face of Antibiotic Resistance: Prevailing Problems and Preventive Measures
Current Drug Metabolism Vitamin D: A Micronutrient Regulating Genes
Current Pharmaceutical Design In Search of Drug Targets for Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Pharmacological Therapy of Pericardial Diseases
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Topical Antimicrobials for Burn Wound Infections
Recent Patents on Anti-Infective Drug Discovery Recent Advances in Medicinal Chemistry to Treat Tuberculosis – Part-II
Current Topics in Medicinal Chemistry Investigation of Antituberculosis from Medicinal Plant of Community Ethnic in South Sulawesi
Infectious Disorders - Drug Targets Oxazolidinone-containing Hybrids with Antibacterial Activity against Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA): A Mini-review
Current Topics in Medicinal Chemistry Cannabinoids: Occurrence and Medicinal Chemistry
Current Medicinal Chemistry Synthesis of 99mTc-Rifabutin: A Potential Tuberculosis Radiodiagnostic Agent
Infectious Disorders - Drug Targets Inhibitors of the Sulfur Assimilation Pathway in Bacterial Pathogens as Enhancers of Antibiotic Therapy
Current Medicinal Chemistry TNF α Signaling Beholds Thalidomide Saga: A Review of Mechanistic Role of TNF-α Signaling Under Thalidomide
Current Topics in Medicinal Chemistry The Aging of the Adaptive Immune System
Current Immunology Reviews (Discontinued) New Strategy on Antimicrobial-resistance: Inhibitors of DNA Replication Enzymes
Current Medicinal Chemistry Chemical Constituents of Plants from the Genus Valeriana
Mini-Reviews in Organic Chemistry Adenovirus and Post-Infectious Bronchiolitis Obliterans in Children
Current Pediatric Reviews Meet Our Editorial Board Member
Infectious Disorders - Drug Targets Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 1: General Overview with a Focus on Ascorbic Acid
Inflammation & Allergy - Drug Targets (Discontinued) Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis
Current Gene Therapy